These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 34273485)

  • 1. Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments.
    Trevor J; Lugogo N; Carr W; Moore WC; Soong W; Panettieri RA; Desai P; Trudo F; Ambrose CS
    Ann Allergy Asthma Immunol; 2021 Nov; 127(5):579-587.e1. PubMed ID: 34273485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma.
    Moore WC; Panettieri RA; Trevor J; Ledford DK; Lugogo N; Soong W; Chipps BE; Carr W; Belton L; Gandhi H; Trudo F; Ambrose CS
    Ann Allergy Asthma Immunol; 2020 Sep; 125(3):294-303.e1. PubMed ID: 32304877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic use and outcomes among adults with severe asthma treated by US subspecialists.
    Panettieri RA; Ledford DK; Chipps BE; Soong W; Lugogo N; Carr W; Mohan A; Carstens D; Genofre E; Trudo F; Ambrose CS
    Ann Allergy Asthma Immunol; 2022 Oct; 129(4):467-474.e3. PubMed ID: 35728746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma.
    Chipps BE; Soong W; Panettieri RA; Carr W; Gandhi H; Zhou W; Cook B; Llanos JP; Ambrose CS
    Ann Allergy Asthma Immunol; 2023 Jun; 130(6):784-790.e5. PubMed ID: 36906262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gaps in Care Among Uncontrolled Severe Asthma Patients in the United States.
    Carr T; Tkacz J; Chung Y; Ambrose CS; Spahn J; Rane P; Wang Y; Lindsley AW; Lewing B; Burnette A
    J Allergy Clin Immunol Pract; 2024 Jul; 12(7):1775-1782.e2. PubMed ID: 38508336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of benralizumab in US subspecialist-treated adults with severe asthma: Findings from CHRONICLE.
    Panettieri RA; Lugogo N; Moore WC; Chipps BE; Jepson B; Zhou W; Ambrose CS; Genofre E; Carstens DD
    Respir Med; 2023 Sep; 216():107285. PubMed ID: 37290579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe asthma exacerbation rates are increased among female, Black, Hispanic, and younger adult patients: results from the US CHRONICLE study.
    Lugogo N; Judson E; Haight E; Trudo F; Chipps BE; Trevor J; Ambrose CS
    J Asthma; 2022 Dec; 59(12):2495-2508. PubMed ID: 35000529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use.
    Jackson DJ; Burhan H; Menzies-Gow A; Pfeffer P; Nanzer A; Garcia Gil E; Morris T; Tran TN; Hirsch I; Dube S
    J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1534-1544.e4. PubMed ID: 35202871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
    Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
    J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asthma exacerbation rates in adults are unchanged over a 5-year period despite high-intensity therapy.
    Schatz M; Meckley LM; Kim M; Stockwell BT; Castro M
    J Allergy Clin Immunol Pract; 2014; 2(5):570-4.e1. PubMed ID: 25213050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes.
    McDowell PJ; Busby J; Hanratty CE; Djukanovic R; Woodcock A; Walker S; Hardman TC; Arron JR; Choy DF; Bradding P; Brightling CE; Chaudhuri R; Cowan D; Mansur AH; Fowler SJ; Diver SE; Howarth P; Lordan J; Menzies-Gow A; Harrison T; Robinson DS; Holweg CTJ; Matthews JG; Pavord ID; Heaney LG
    Am J Respir Crit Care Med; 2022 Sep; 206(5):545-553. PubMed ID: 35549845
    [No Abstract]   [Full Text] [Related]  

  • 13. Suboptimal Response to Biologics in Severe Asthma-A Marker of Humoral Immunodeficiencies.
    Tiotiu A; De Meulder B; Vaillant P; Mouton-Faivre C; Jaussaud R
    J Allergy Clin Immunol Pract; 2024 Jul; 12(7):1840-1849.e3. PubMed ID: 38548169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults.
    Petsky HL; Li A; Chang AB
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD005603. PubMed ID: 28837221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study.
    Price DB; Rigazio A; Campbell JD; Bleecker ER; Corrigan CJ; Thomas M; Wenzel SE; Wilson AM; Small MB; Gopalan G; Ashton VL; Burden A; Hillyer EV; Kerkhof M; Pavord ID
    Lancet Respir Med; 2015 Nov; 3(11):849-58. PubMed ID: 26493938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.
    Porsbjerg CM; Townend J; Bergeron C; Christoff GC; Katsoulotos GP; Larenas-Linnemann D; Tran TN; Al-Lehebi R; Bosnic-Anticevich SZ; Busby J; Hew M; Kostikas K; Papadopoulos NG; Pfeffer PE; Popov TA; Rhee CK; Sadatsafavi M; Tsai MJ; Ulrik CS; Al-Ahmad M; Altraja A; Beastall A; Bulathsinhala L; Carter V; Cosio BG; Fletton K; Hansen S; Heaney LG; Hubbard RB; Kuna P; Murray RB; Nagano T; Pini L; Cano Rosales DJ; Schleich F; Wechsler ME; Amaral R; Bourdin A; Brusselle GG; Chen W; Chung LP; Denton E; Fonseca JA; Hoyte F; Jackson DJ; Katial R; Kirenga BJ; Koh MS; Ławkiedraj A; Lehtimäki L; Liew MF; Mahboub B; Martin N; Menzies-Gow AN; Pang PH; Papaioannou AI; Patel PH; Perez-De-Llano L; Peters MJ; Ricciardi L; Rodríguez-Cáceres B; Solarte I; Tay TR; Torres-Duque CA; Wang E; Zappa M; Abisheganaden J; Assing KD; Costello RW; Gibson PG; Heffler E; Máspero J; Nicola S; Perng Steve DW; Puggioni F; Salvi S; Sheu CC; Sirena C; Taillé C; Tan TL; Bjermer L; Canonica GW; Iwanaga T; Jiménez-Maldonado L; Taube C; Brussino L; Price DB
    Front Immunol; 2024; 15():1361891. PubMed ID: 38711495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma.
    Zeiger RS; Schatz M; Li Q; Chen W; Khatry DB; Gossage D; Tran TN
    J Allergy Clin Immunol Pract; 2014; 2(6):741-50. PubMed ID: 25439366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Subspecialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study.
    Moore WC; Ledford DK; Carstens DD; Ambrose CS
    J Asthma Allergy; 2022; 15():1195-1203. PubMed ID: 36068863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
    Menzella F; Bargagli E; Aliani M; Bracciale P; Brussino L; Caiaffa MF; Caruso C; Centanni S; D'Amato M; Del Giacco S; De Michele F; Di Marco F; Pastorello EA; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Vultaggio A; Simoni L; Ori A; Boarino S; Vitiello G; Altieri E; Canonica GW
    Respir Res; 2022 Feb; 23(1):36. PubMed ID: 35183167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.